Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 16, 2022

Fulvestrant, Everolimus, and Anastrozole for the Front-Line Treatment of Advanced HR+ Breast Cancer

Clinical Cancer Research


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222
Clin. Cancer Res 2022 Jan 04;[EPub Ahead of Print], HCF Moore, WE Barlow, G Somlo, JR Gralow, AF Schott, DF Hayes, P Kuhn, JB Hicks, L Welter, PA Dy, CH Yeon, AK Conlin, E Balcueva, DL Lew, D Tripathy, L Pusztai, GN Hortobagyi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading